 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
15 News |  |
- | AP-SA01 / Armata
Preclinical, Journal: Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus. (Pubmed Central) - Jul 21, 2021
Topical application of phage cocktail AB-SA01 is effective, as shown by bacterial load reduction and wound closure, in the treatment of diabetic wound infections caused by MDR S. aureus. Our results suggest that topical phage cocktail treatment may be effective in treating antibiotic-resistant S. aureus DFU infections.
- || AP-SA01 / Armata
PK/PD data, Preclinical, Journal, Combination therapy: Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain: In vitro Pharmacokinetic/Pharmacodynamic Model. (Pubmed Central) - Jun 22, 2021
In addition, BACs resulted in enhancement in bacterial eradication in SEV models. Our findings support the potential activity of BAC therapy for combating serious methicillin-resistant Staphylococcus aureus (MRSA) infections.
- | AP-SA01 / Armata
Preclinical, Journal: Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms. (Pubmed Central) - Feb 12, 2021
The in vitro lytic efficacies of phage cocktails AB-SA01, AB-PA01, which target Staphylococcus aureus and Pseudomonas aeruginosa, respectively, and their combination against their hosts were evaluated in S. aureus and P. aeruginosa mixed-species planktonic and biofilm cultures...This study result shows that these phage cocktails lyse their hosts in the presence of non-susceptible bacteria. These data support the use of phage cocktails therapy in infections with multiple bacterial species.
- || AP-SA01 / Armata
Clinical, Journal: Safety of bacteriophage therapy in severe Staphylococcus aureus infection. (Pubmed Central) - Jul 21, 2020
No adverse reactions were reported, and our data indicate that AB-SA01 administered in this way is safe in severe S. aureus infections, including infective endocarditis and septic shock. Future controlled trials will be needed to determine the efficacy of AB-SA01 but no phage resistance evolved in vivo and the measurements of bacterial and phage kinetics in blood samples suggest that 12 h dosing of 10 plaque-forming units may be a rational basis for further studies.
- | AB-SA01 / AmpliPhi
Clinical, Journal: Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due to Staphylococcus aureus. (Pubmed Central) - Jun 21, 2019
...To investigate the safety, tolerability, and preliminary efficacy of ascending multiple intranasal doses of investigational phage cocktail AB-SA01 in patients with recalcitrant CRS due to S aureus...Phage therapy could be an alternative to antibiotics for patients with CRS. http://anzctr.org.au identifier: ACTRN12616000002482.
- | AB-SA01 / AmpliPhi
Preclinical, Journal: Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections. (Pubmed Central) - Jun 7, 2019
In both neutropenic and immunocompetent mouse models of acute pneumonia, AB-SA01 reduced lung S. aureus populations equivalently to vancomycin. Overall, the inherent characteristics of AB-SA01 component phages meet regulatory and generally accepted criteria for human use, and the preclinical data presented here have supported production under good manufacturing practices and phase 1 clinical studies with AB-SA01.
- AP-SA01 / Armata
Safety and efficacy of bacteriophage therapy: the Australian experience (HALL N) - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_4442;
Decrease in Staphylococcal DNA load during BT is reflected in improvement of objective clinical criteria. Bacteriophage titre rapidly decreased after IV administration.
- AP-SA01 / Armata
New trial: Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic (clinicaltrials.gov) - Jan 10, 2018
P=N/A, N=0, Available, Sponsor: AmpliPhi Biosciences Corporation
- | AP-SA01 / Armata
Trial completion: Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults (clinicaltrials.gov) - Aug 31, 2016
P1, N=12, Completed, Sponsor: AmpliPhi Biosciences Corporation
Bacteriophage titre rapidly decreased after IV administration. Recruiting --> Completed
- AP-SA01 / Armata
Enrollment open: Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults (clinicaltrials.gov) - May 29, 2016
P1, N=12, Recruiting, Sponsor: AmpliPhi Biosciences Corporation
Recruiting --> Completed Not yet recruiting --> Recruiting
- AP-SA01 / Armata
New P1 trial: Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults (clinicaltrials.gov) - May 2, 2016
P1, N=12, Not yet recruiting, Sponsor: AmpliPhi Biosciences Corporation